Clearside Completes Enrollment in First Phase III Trial of CLS-TA in RVO

June 29, 2018: By Jon Swedien

Clearside Biomedical has completed enrollment in its first Phase III clinical trial studying suprachoroidal CLS-TA used with aflibercept for retinal vein occlusion (RVO), the Alpharetta, Georgia, company announced June 13.

SAPPHIRE is a multicentered, multi-country, randomized, masked, controlled study of 460 patients who are naïve to pharmacologic treatment for RVO.

It will assess whether using suprachoroidal CLS-TA in combination with Eylea offers an opportunity for earlier improved visual outcomes for RVO patients compared with Eylea monotherapy.

The study is also designed to evaluate required treatment frequency for the combination arm compared with the Eylea control arm over the course of the trial.

The company expects to report topline data from the week eight primary endpoint in Q4-2018.

CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space.

It has been observed to reduce inflammation and other complications that lead to swelling of the macula, a leading cause of visual impairment and blindness, Clearside said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023